HomeCompareADXS vs ADC

ADXS vs ADC: Dividend Comparison 2026

ADXS yields 331.37% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADXS wins by $2987.13M in total portfolio value
10 years
ADXS
ADXS
● Live price
331.37%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2987.30M
Annual income
$1,874,518,858.21
Full ADXS calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — ADXS vs ADC

📍 ADXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADXSADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADXS + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADXS pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADXS
Annual income on $10K today (after 15% tax)
$28,166.68/yr
After 10yr DRIP, annual income (after tax)
$1,593,341,029.48/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADXS beats the other by $1,593,273,329.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADXS + ADC for your $10,000?

ADXS: 50%ADC: 50%
100% ADC50/50100% ADXS
Portfolio after 10yr
$1493.74M
Annual income
$937,299,252.73/yr
Blended yield
62.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ADXS
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-24.8
Piotroski
1/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADXS buys
0
ADC buys
0
No recent congressional trades found for ADXS or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADXSADC
Forward yield331.37%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$2987.30M$176.9K
Annual income after 10y$1,874,518,858.21$79,647.25
Total dividends collected$2879.16M$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ADXS vs ADC ($10,000, DRIP)

YearADXS PortfolioADXS Income/yrADC PortfolioADC Income/yrGap
1← crossover$43,837$33,137.27$10,987$577.21+$32.9KADXS
2$182,667$135,761.45$12,293$855.34+$170.4KADXS
3$724,155$528,700.93$14,088$1,290.70+$710.1KADXS
4$2,733,677$1,958,830.81$16,660$1,994.91+$2.72MADXS
5$9,835,841$6,910,807.10$20,525$3,181.85+$9.82MADXS
6$33,762,918$23,238,567.70$26,654$5,286.90+$33.74MADXS
7$110,677,420$74,551,098.17$37,006$9,259.47+$110.64MADXS
8$346,821,277$228,396,437.05$55,862$17,338.74+$346.77MADXS
9$1,039,984,991$668,886,225.19$93,452$35,300.32+$1039.89MADXS
10$2,987,302,799$1,874,518,858.21$176,931$79,647.25+$2987.13MADXS

ADXS vs ADC: Complete Analysis 2026

ADXSStock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Full ADXS Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ADXS vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADXS vs SCHDADXS vs JEPIADXS vs OADXS vs KOADXS vs MAINADXS vs NNNADXS vs EPRTADXS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.